Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:24 AM
Ignite Modification Date: 2025-12-25 @ 12:24 AM
NCT ID: NCT04736758
Eligibility Criteria: Inclusion Criteria: * Positive Influenza rapid antigen test; * Fever (axillary temperature ≥37.3℃) or the axillary temperature ≥37.3℃ after taking the medicine for more than 4 hours; * At least one systemic symptom and respiratory symptom related to a moderate or above influenza virus infection: 1. Systemic symptoms: headache, fever or chills, muscle or joint aches, fatigue; 2. Respiratory system symptoms: cough, sore throat, nasal congestion. * Time of disease symptoms ≤48h Exclusion Criteria: * Diagnosed as severe influenza patient ; * Known history of dysphagia or any gastrointestinal disease that affects drug absorption (including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, stomach After subtotal resection, etc.); * Have used anti-influenza virus drugs (oseltamivir, zanamivir, peramivir, favipiravir, abidol, baloxavir dipivoxil, amantadine, or diamond) within 2 weeks before screening Ethylamine, etc.); * Acute respiratory infections, otitis media, sinusitis or other infectious diseases such as bronchitis, pneumonia, tuberculosis, etc. occurred within 2 weeks before screening, and are in the acute stage; * Patients who also suffer from bacterial or viral infections and need systemic antibacterial or antiviral therapy
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 65 Years
Study: NCT04736758
Study Brief:
Protocol Section: NCT04736758